Skip to main content
Clinical Trials/NCT03129737
NCT03129737
Unknown
Not Applicable

Multi-centre Randomised Trial Investigating the Effect of PROphylactic triCuspID Annuloplasty in Patients With Dilated Tricuspid Annulus on Tricuspid Regurgitation Progression, Right Ventricular Remodeling and Functional Outcomes

Ettore Sansavini Health Science Foundation8 sites in 1 country200 target enrollmentMay 17, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Tricuspid (Valve) Insufficiency (Rheumatic)
Sponsor
Ettore Sansavini Health Science Foundation
Enrollment
200
Locations
8
Primary Endpoint
Progression of TR
Last Updated
8 years ago

Overview

Brief Summary

Patients elected to undergo mitral valve surgery (either repair or replacement) with less equal than moderate (≤+2) tricuspid regurgitation and dilated tricuspid annulus (>21mm/m2) at preoperative echocardiography will be screened. Consenting patients fulfilling all inclusion and exclusion criteria will be included in the study and assigned to elective mitral valve replacement or repair with or without concomitant tricuspid annuloplasty in a 1:1 fashion, using a blocked randomization scheme balanced within center.

Detailed Description

The present study is designed as a prospective, multicentre, multinational, randomized, 2-arm parallel group trial. Participating centres are selected based on previous experience with the surgical technique and standardised echo imaging. Each center is expected to contribute 20 to 40 patients over a 12-month enrolment period. Patients elected to undergo mitral valve surgery (either repair or replacement) with less equal than moderate (≤+2) tricuspid regurgitation and dilated tricuspid annulus (\>21mm/m2) at preoperative echocardiography will be screened. Consenting patients fulfilling all inclusion and exclusion criteria will be included in the study and assigned to elective mitral valve replacement or repair with or without concomitant tricuspid annuloplasty in a 1:1 fashion, using a blocked randomization scheme balanced within center. After discharge patients will be assessed at 1 month (phone contact), 6 month and 1-year after surgery.

Registry
clinicaltrials.gov
Start Date
May 17, 2017
End Date
June 2020
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Ettore Sansavini Health Science Foundation
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing mitral valve surgery (either repair or replacement) with less/equal than moderate (≤+2) tricuspid regurgitation and dilated tricuspid annulus (\>21mm/m2 BSA) at preoperative echocardiography and fulfilling the following selection criteria:
  • Inclusion criteria:
  • Written informed consent
  • Degenerative mitral valve disease
  • \> 18 years old

Exclusion Criteria

  • Main exclusion criteria:
  • Presence of structural or organic tricuspid valve disease
  • urgent operation
  • presence of pacemaker leads through the tricuspid annulus
  • acute endocarditis or other organic valve diseases
  • previous surgical procedure
  • Associated cardiac procedure
  • NYHA class IV
  • Severe COPD (GOLD class 3,4)

Outcomes

Primary Outcomes

Progression of TR

Time Frame: 1 year

Progression of TR at one year follow-up defined as worsening of at least one class with respect to pre-surgery as assessed by the Core lab evaluation of the echocardiogram.

Secondary Outcomes

  • Evaluation of reverse right ventricle (RV) remodelling(1 year)
  • Residual TR(1 year)

Study Sites (8)

Loading locations...

Similar Trials